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In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on
tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas
overexpression of Bcl-2 had no effect. Mithramycin also potentiated cell death induced by Fas agonistic antibodies. In contrast,
mithramycin reduced the percentage of cells undergoing apoptosis due to factor withdrawal. TNF-induced activation of NF-kappaB
(NF-kB)-dependent gene expression was not modulated by mithramycin treatment. Concomitantly with the increased sensitivity, the
protein level of the short-spliced cFLIP variant was downregulated. These results indicate that mithramycin enhances TNF-induced
cell death in an NF-kB-independent manner, and suggest that the Fas-associated death domain protein plays a crucial role in the TNF-
sensitising effect of mithramycin.
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Mithramycin A (trade name Plicamycin) is an anticancer drug
used to treat several types of cancer including chronic myeloid
leukaemia and acute myeloid leukaemia (Koller and Miller, 1986;
Queisser et al, 1988). Its mechanism of action involves a reversible
interaction with double-stranded DNA with GC base specificity. It
is believed to act, in part, by selectively inhibiting transcription of
genes that have GC-rich promoter sequences (Miller et al, 1987). In
this regard, mithramycin has been shown to prevent resistance to
chemotherapeutic agents, by a number of mechanisms including
downregulation of proteins, such as multidrug resistance gene 1
(Tagashira et al, 2000). Since most chemotherapeutic drugs are
known to activate the process of apoptosis, dysregulation of this
process can affect treatment sensitivity. Understanding the
mechanism of action of mithramycin in combination with various
apoptotic stimuli could lead to strategies resulting in improved
therapeutic benefits.
Cells are responsive to a multitude of signals that they encounter
in their extracellular environment. One such signal with wide-
spread pleiotropic actions is the cytokine tumour necrosis factor-
alpha (TNF). Differential responses to this cytokine are thought to
be due to different intracellular signalling pathways (Leong and
Karsan, 2000). One major signalling pathway leads to the induction
of apoptosis through the activation of caspase-8 or -10 via TNF
receptor-associated death domain (TRADD) and Fas-associated
death domain (FADD) (Hsu et al, 1996). Activated caspases then
cleave downstream substrates that initiate the execution of
apoptosis, such as caspase-3, or amplify the programmed cell
death signal, through cleavage of BID and activation of the
mitochondrial apoptotic pathway. Apoptosis initiated by Fas
triggering follows a similar pathway, but in this case FADD is
directly recruited to the Fas receptor without the involvement of
TRADD (Chinnaiyan et al, 1996). To prevent inappropriate
apoptosis, the death receptor signalling is controlled at different
checkpoints: namely at the receptor level by modulation of the
receptor, or soluble ligands; during signal transduction by FLIP
and Bcl-2 proteins, or during the effector phase by inhibitors of
apoptosis (IAPs). Another major signalling pathway leads to the
activation of the transcription factor nuclear factor-kappaB (NF-
kB). Nuclear factor-kappaB is believed to be activated via TRADD
and TNF receptor-associated factor-2(TRAF2), and/or receptor
interacting protein (RIP) (Kelliher et al, 1998). Activation of NF-kB
induces protective mechanisms by stimulation of the expression of
regulator proteins with potential antiapoptotic activity, such as the
IAP proteins (Beg and Baltimore, 1996; Van Antwerp et al, 1996).
Tumour necrosis factor receptors are expressed on a variety of
different cell types, yet many TNF-receptor-expressing cells are
resistant to TNF-induced apoptosis. The latter and the proin-
flammatory effects of TNF that lead to several toxic side effects in
vivo, have limited the use of TNF as an antitumour agent
(Kettelhut et al, 1987). However, combination treatments that
allow the use of lower nontoxic doses and/or prevent cell resistance
might still offer opportunities for TNF in the treatment of cancer
(Wajant et al, 2000; Schotte et al, 2001). In view of the reported use
of mithramycin A in preventing chemotherapy resistance, we
investigated the effect of mithramycin in TNF-induced cell death.
MATERIALS AND METHODS
Cell lines and reagents
All human cell lines were obtained from the ATCC. TF-1, a human
GM-CSF-dependent erythroleukaemic cell line (Kitamura et al,
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s1989), was maintained in logarithmic growth at 210
5cellsml
1
in complete RPMI 1640 medium containing 10% foetal calf serum
(FCS) and 10% hGM-CSF-conditioned medium (complete med-
ium). hGM-CSF-conditioned medium was obtained from stably
transduced human embryonic kidney 293 cells with a pLHCX
plasmid (Clontech, Oxford, UK) encoding the human GM-CSF
protein. The HL60 promyelocytic leukaemia and U937 human
histiocytic lymphoma cell lines were maintained in RPMI 1640
medium containing 10% FCS. The GM-CSF producing HEK-293
cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FCS. The caspase inhibitor
zVAD-fmk, the transcription inhibitor actinomycin D and the
antimitotic agent aphidicolin were supplied by Sigma, Dublin, Irl.
Recombinant human TNF was purchased from R&D systems,
Abington, UK. Anti-Fas antibodies (agonistic antibodies; clone
CH-11) and anti-FLIP g/d antibodies were obtained from MBL,
MA, USA and Calbiochem, Nottingham, UK respectively. Mithra-
mycin A was purchased from Tocris, Bristol, UK.
Cell treatments
For GM-CSF withdrawal experiments, TF-1 cells were washed twice
in Hank’s buffered saline solution, then resuspended in RPMI 1640
medium containing 10% FCS in the presence or absence of 75nM
mithramycin. For combination experiments with TNF or anti-Fas,
cells were maintained in complete medium and treated with
mithramycin simultaneously to the different drugs.
Quantification of apoptosis
Cell cycle status and quantification of DNA fragmentation was
performed by propidium iodide (PI) staining according to
Darzynkiewicz (Darzynkiewicz et al, 2001). DNA content was
determined using a FACSCalibur (Becton Dickinson, Oxford, UK)
flow cytometer. Data were analysed by Cellquest software.
Quantification of apoptosis by phosphatidylserine exposure was
assessed by annexin V staining using the Alexa Flour 488 kit
(Molecular Probes, Rijnsburgerweg, The Netherlands), according
to the manufacturer’s instruction.
Generation of cells stably expressing an NF-jB reporter
plasmid
TF-1 cells were stably transfected with the pNF-kB-hrGFP plasmid
(Stratagene, Amsterdam, The Netherlands) expressing a hrGFP
gene controlled by a synthetic promoter that contains five binding
sites for NF-kB. A measure of 5mg of reporter plasmid was
transfected with lipofectin (Gubina et al, 1998).
Western blot analysis
Proteins were extracted in RIPA buffer (50mM Tris, 1% NP40,
150mM NaCl, 1mM EGTA) with complete protease inhibitor mix
from Roche, East Sussex, UK. In total, 30mg of protein were
separated by sodium dodecyl sulphate–polyacrylamide gel elec-
trophoresis (12% SDS–PAGE), transferred to a nitrocellulose
membrane and immunoblotted with the indicated antibody.
Immunoreactive proteins were detected by enhanced chemilumi-
nescence (ECL, Amersham, Bucks, UK).
Statistical analysis
All results were expressed as the mean7s.d. of three independent
experiments performed in duplicate. These data were analysed
using Student’s t-test for paired comparisons. Statistical signifi-
cance was determined as Po0.05.
RESULTS
Co-treatment with mithramycin increases the cytotoxicity
effect of TNF in tumour cells
Since the TF-1 erythroleukaemia cell line is relatively resistant to
apoptosis induced by TNF, we first investigated whether sublethal
concentrations of mithramycin would affect cells sensitivity to
TNF-mediated apoptosis. Cell death, that is the percentage of cells
with fragmented DNA in subG1, was quantified by flow cytometry
following PI staining. As shown in Figure 1A, there was little effect
on DNA fragmentation and cell cycle distribution after 48h of
exposure to either agent alone. However, in the presence of both
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Figure 1 Mithramycin increased TNF-induced cell death in TF-1 cells.
(A) TF-1 cells were treated with 20ngml
1 TNF-alpha (TNF) in the
presence or absence of increasing concentrations of mithramycin. After
48h of incubation, DNA profiles were established by flow cytometry
following PI staining. (B) TF-1 cells were treated for the indicated periods
with 20ngml
1 TNF in the presence or absence of 75nM mithramycin.
Percentage of subG1 cells was determined by PI staining of ethanol-fixed
cells and analysed by flow cytometry. *, Po0.05; **, Po0.01 of three
independent experiments compared to TNF-treated cells.
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smithramycin and TNF, TF-1 cells underwent significant cell death.
Mithramycin-mediated sensitisation was dose dependent and was
detected after 24h incubation with TNF (Figure 1B).
To study whether the observed sensitisation was specific to TF-1
cells, we tested the TNF sensitivity of two additional cell lines:
HL60 promyelocytic leukaemia and the U937 human histiocytic
lymphoma cell lines (Figure 2). Both cell lines displayed modest
sensitivity to TNF. However, when the cells were cotreated with
mithramycin, their sensitivity towards TNF was doubled as
quantified by flow cytometry.
To further elucidate the sensitisation effects of mithramycin, we
focused our studies on the erythroleukaemic cell line TF-1.
Sensitisation to TNF-induced apoptosis by mithramycin is
caspase dependent but is not prevented by Bcl-2
overexpression
To confirm that the cell death induced by mithramycin in TNF-
treated cells was due to apoptosis, TF-1 cells were simultaneously
stained with PI and annexin V, and analysed by flow cytometry
(Figure 3A). Following TNF treatment, 22.10% of cells stained
positive with annexin V and negative with PI, indicating that they
were undergoing apoptosis. At this time point, an additional 5.60%
of the cells stained positive for both annexin V and PI,
representing cells undergoing late apoptosis/secondary necrosis.
Cotreatment with mithramycin increased the percentage of cells
stained positive for annexin V and negative for PI to 46.33%,
whereas cells positive for both PI and annexin remain relatively
unchanged (6.08%).
To evaluate the role of caspases in mithramycin-mediated
sensitisation to TNF, we treated TF-1 cells with TNF and/or
mithramycin in the presence of the caspase inhibitor, z-VAD-fmk.
Treatment of cells with 50mM z-VAD-fmk prevented mithramycin/
TNF-induced DNA fragmentation (Figure 3B).
Next, we examined whether mithramycin-mediated sensitisation
was modulated by overexpression of Bcl-2. Bcl-2 is believed to
prevent caspase activation by blocking the mitochondrial pathway
(Yang et al, 1997). A vector containing the green fluorescent
protein (GFP) gene and the antiapoptotic bcl-2 gene together with
an internal ribosome entry site (IRES) sequence was used, allowing
us to analyse the percentage of cells stably expressing GFP/Bcl-2.
As represented in Figure 4A, more than 76% of GFP/Bcl-2-
transfected cells expressed GFP, and this percentage was not
modulated in the presence of mithramycin, demonstrating that
mithramycin was not affecting expression of the bcl-2 gene. To
further establish whether expressed Bcl-2 was functionally active,
cells were depleted with GM-CSF. The TF-1 cell line has been
reported to undergo apoptosis upon growth factor deprivation
(Kolonics et al, 2001), which can be suppressed by overexpression
of Bcl-2 (Kitamura et al, 1989; Alvarado-Moreno et al, 2000). Upon
GM-CSF withdrawal (Figure 4B), 30% of the control cell
population underwent apoptosis as determined by the number of
cells with fragmented DNA (subG1), whereas in bcl-2-transfected
cells DNA fragmentation was inhibited completely. Therefore, the
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Figure 3 Sensitisation to TNF-induced apoptosis by mithramycin is
caspase dependent. TF-1 cells were treated with 20ngml
1 TNF in the
presence or absence of 75nM mithramycin. (A) After 24h of incubation,
cells were stained with annexin V and PI. Necrosis (N) and apoptosis (A)
were quantified by flow cytometry. The annexin V-positive cells are the
cells undergoing apoptosis and are represented in the lower right quadrant.
Similar results were obtained from two more independent experiments.
(B) Effect of 50mM caspase inhibitor zVAD-fmk. Percentage of subG1 cells
was determined by PI staining and analysed by flow cytometry. *, Po0.05;
**, Po0.01 of three independent experiments compared to TNF-treated
cells.
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Figure 2 Mithramycin increased TNF-induced cell death in HL60 and
U937 cells. HL60 (A) and U937 (B) cells were treated with 20ngml
1
TNF in the presence or absence of 75nM mithramycin. Percentage of
subG1 cells was determined by PI staining and analysed by flow cytometry.
**, Po0.01 of three independent experiments compared to TNF-treated
cells.
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sbcl-2-transfected cells, which were recognised by their GFP
fluorescence, overexpressed a functional Bcl-2 protein. TF-1 cells
overexpressing Bcl-2 were treated with increasing concentrations
of TNF in the presence or absence of mithramycin for 24h, and
then assessed for DNA fragmentation by flow cytometry. As shown
in Figure 4B, Bcl-2 overexpression did not prevent mithramycin-
mediated sensitisation to TNF. In agreement with these results, no
loss of the mitochondrial membrane potential was observed
following 24h treatment with TNF and mithramycin (data not
shown).
Cotreatment with mithramycin increases the cytotoxic
effect of anti-Fas antibodies in TF-1 cells
Since both TNF and Fas receptors engage a common component to
the apoptotic machinery (Chinnaiyan et al, 1996), we tested
whether mithramycin would also have a synergistic effect on
apoptosis in response to Fas ligation in TF-1 cells. TF-1 cells were
treated with Fas agonistic antibodies in the presence or absence of
mithramycin, and then assessed for DNA fragmentation. There was
little effect on the viability of TF-1 cells after 48h exposure to
either agent alone; however, in the presence of both mithramycin
and anti-Fas antibodies, TF-1 cells underwent significant cell death
(Figure 5A). Similar to TNF/mithramycin combination, induction
of apoptosis by anti-Fas and mithramycin cotreatment was not
blocked by bcl-2 overexpression (Figure 5B).
Next, to study whether the observed sensitisation was specific to
death receptor signalling events, we tested the effect of mithra-
mycin on apoptosis in response to growth factor depletion.
Mithramycin appeared to delay the induction of apoptosis in TF-1
cells following GM-CSF removal (Figure 5C). GM-CSF depletion is
reported to trigger apoptosis independent of death receptor
signalling (Raff, 1998; Klampfer et al, 1999). Furthermore, we
demonstrated in Figure 4B that overexpression of Bcl-2 prevented
apoptosis after growth factor depletion. Altogether, these data
would suggest that mithramycin-mediated sensitisation depends
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Figure 4 Sensitisation to TNF-induced apoptosis by mithramycin is not
prevented by Bcl-2 overexpression. (A) Analysis of GFP expression in TF-1
cells. Mock-transfected (control) TF-1 cells and cells stably transfected with
GFP/bcl-2 expression vector were analysed by flow cytometry. GFP/bcl-2-
transfected cells were identified by their GFP fluorescence. (B) Mock-
transfected (control) TF-1 cells and cells stably transfected with GFP/bcl-2
(bcl-2) were depleted of GM-CSF or treated with increasing concentrations
of TNF in the presence or absence or 75nM mithramycin. After 24h of
incubation, percentage of subG1 cells were determined by PI staining and
analysed by flow cytometry. Data are representative of three independent
experiments performed in duplicate. *, Po0.05 compared to GM-CSF-
depleted mock-transfected cells.
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Figure 5 Sensitisation to Fas-induced, but not to GM-CSF withdrawal-
induced apoptosis by mithramycin. (A) TF-1 cells were treated with
increasing concentrations of anti-Fas antibodies in the presence or absence
of 75nM mithramycin. After 48h of incubation, percentage of subG1 cells
were determined by PI staining and analysed by flow cytometry. *, Po0.05;
**, Po0.01 of three independent experiments. (B) Mock-transfected
(control) TF-1 cells and cells stably transfected with GFP/bcl-2 (bcl-2) were
treated with 100 or 200ngml
1 anti-Fas antibodies in the presence or
absence or 75nM mithramycin. After 24h of incubation, percentage of
subG1 cells were determined by PI staining and analysed by flow
cytometry. Data are representative of three independent experiments
performed in duplicate. (C) TF-1 cells were depleted of GM-CSF in the
presence or absence of 75nM mithramycin. After 48h of incubation, cells
were collected and stained with PI and annexin V. Necrosis (N) and
apoptosis (A) were quantified by flow cytometry. Similar results were
obtained from two more independent experiments.
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son the signalling pathway involved in the induction of apoptosis,
and that the proapoptotic function of mithramycin involves death
receptor-associated signalling events.
Pretreatment is sufficient to significantly increase TNF-
induced DNA fragmentation. Comparison with
actinomycin D and aphidicolin
Next, we examined whether pretreatment with mithramycin
sensitises TF-1 cells to TNF-induced DNA fragmentation. As
shown in Figure 6, pretreatment with mithramycin for only 4h
significantly enhanced sensitivity to TNF-induced apoptosis.
Several studies indicate that transcriptional or translational
inhibition enhanced the cytotoxic effect of death receptors in
various types of cancer (Fulda et al, 2000; Wajant et al, 2000).
Others studies demonstrate the involvement of DNA injury in
potentiating TNF-induced apoptosis in cells treated with nontoxic
concentrations of aphidicolin (Gera et al, 1993). Since mithramy-
cin is reported to inhibit transcription and prevents DNA
replication too, both effects of mithramycin could explain the
sensitisation to TNF-induced apoptosis. To distinguish between
these two effects, mithramycin-mediated sensitisation was com-
pared to transcription and replication inhibitors, namely, actino-
mycin D and aphidicolin, respectively. In Figure 6, the percentage
of cells with fragmented DNA in TF-1 cells pretreated with
actinomycin D, mithramycin and aphidicolin and then incubated
with TNF is represented. Whereas actinomycin D increased TNF-
induced DNA fragmentation, the inhibitor of DNA replication
aphidicolin had no effect on TNF-induced DNA fragmentation.
These results suggest that the sensitising effects of mithramycin
could be explained as a result of transcription inhibition.
Mithramycin-mediated sensitisation to TNF-induced apoptosis
may prevent the synthesis of short-lived inhibitors of apoptosis.
Mithramycin-induced TNF sensitisation does not prevent
NF-jB activation
In addition to the induction of the proapoptotic pathway, TNF
activates the transcription factor NF-kB, and this response
potently suppresses the apoptotic potential of these stimuli in
vitro (Beg and Baltimore, 1996; Ponton et al, 1996; Van Antwerp
et al, 1996). To analyse whether mithramycin increased TNF-
induced cell death by preventing TNF-induced NF-kB activation,
we studied the effect of mithramycin on the TNF-induced
expression of an NF-kB-dependent reporter gene in TF-1 cells.
TF-1 cells stably expressing an NF-kB-dependent hrGFP reporter
gene were either untreated, or treated with 75nM mithramycin and
simultaneously stimulated for 10h with a serial dilution of TNF. As
shown in Figure 7, no effect of mithramycin on NF-kB-dependent
gene expression was detected, indicating that mithramycin did not
prevent NF-kB activation following TNF stimulation.
Decrease in cFLIP protein level after treatment with TNF
and mithramycin
Since TNF-induced apoptosis, but not TNF-mediated NF-kB
activation, required the presence of mithramycin, we hypothesised
that the mithramycin-sensitive factor has to interfere with TNF
signalling downstream of the bifurcation point of apoptosis and
NF-kB activation. A known receptor-proximal regulator of TNF-
and Fas-induced apoptosis is the cellular FLICE inhibitory protein
(cFLIP). We therefore investigated the expression levels of the
short-spliced form of cFLIP in TF-1 cells. As shown in Figure 8, the
expression level of FLIP remained unaffected in mithramycin-
treated cells. Treatment of the cells with TNF alone appeared to
decrease the level of cFLIP protein at 24h, however, expression
levels recovered by 48h. When cells were simultaneously treated
with TNF and mithramycin, levels of cFLIP protein significantly
decreased at 24h, and no recovery in the protein expression was
detected at 48h.
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Figure 6 Enhancement of TNF-induced apoptosis by preincubation with
mithramycin. Comparison to actinomycin D and aphidicolin. TF-1 cells
were either left untreated or were pretreated with actinomycin D (1 and
5mgml
1), mithramycin (40 and 75nM) or aphidicolin (0.75, 1.5 and 3mM)
for 4h, followed by incubation with 20ngml
1 TNF for 24h. Percentage of
subG1 cells were determined by PI staining and analysed by flow
cytometry. *, Po0.05; **, Po0.01 of three independent experiments
compared to untreated cells.
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Figure 7 Mithramycin had no effect on NF-kB-dependent gene
expression in response to TNF. TF-1 cells stably expressing an NF-kB-
dependent hrGFP reporter gene were either untreated or treated with
75nM mithramycin and stimulated for 10h with a serial dilution of TNF.
Cells were then assayed for hrGFP expression by flow cytometry. Data are
representative of two independent experiments performed in duplicate.
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Figure 8 Decreased level of cFLIP protein in response to TNF and
mithramycin. TF-1 cells were treated with 20ngml
1 TNF in the presence
or absence of 75nM mithramycin for 24 or 48h. The expression levels of
short-spliced cFLIP variant and actin were then determined by Western
blot analysis.
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sDISCUSSION
This current report demonstrates that a combination of TNF and
mithramycin enhanced apoptosis of TF-1 cells within 24h, relative
to single treatments of TNF or mithramycin alone. Apoptosis
induced by TNF and mithramycin treatment was effectively
blocked by treatment with z-VAD-fmk peptide, an inhibitor of
caspases, indicating that caspases played a critical role in the
execution phase of apoptosis induced by TNF in the presence of
mithramycin. Studies on the involvement of the mitochondria in
the regulation of apoptosis revealed that TF-1 cells overexpressing
the antiapoptotic protein Bcl-2 were not protected against
apoptosis induced by TNF and mithramycin. These results further
indicate that in the presence of mithramycin, TNF induced
apoptosis via a caspase-signalling cascade that executed apoptosis
independently of the proapoptotic machinery of the mitochondria.
These results support the hypothesis that mithramycin targets an
inhibitor of apoptosis involved in TNF-induced apoptosis, at the
level of death receptor signalling.
Mithramycin also significantly increased apoptosis mediated by
another member of the death receptor family, Fas (CD95/APO-1),
and could not be suppressed by overexpression of Bcl-2,
suggesting the existence of a common mithramycin-sensitive
inhibitor of apoptosis. TNF- and Fas-induced signalling pathways
leading to caspase activation and apoptosis converge at the level of
FADD (Chinnaiyan et al, 1996). Fas directly binds to FADD,
whereas p55 TNF-receptor initiates FADD clustering via the
adaptator protein TRADD. This strongly suggests that the
potentiating effect of mithramycin on Fas and TNF cytotoxicity
is situated at the level of, or downstream of, FADD.
In contrast to the above findings, the current study also
demonstrated that the presence of mithramycin is able to abrogate
cell death induced by growth factor depletion. These observations
are currently the focus of another study, however, it is in
agreement of earlier observations that GM-CSF withdrawal in
factor-dependent cell lines induces apoptosis in a manner
independent of death receptor signalling (Raff 1998; Klampfer
et al, 1999).
In the present study, we report that the sensitisation effect of
mithramycin to TNF-induced apoptosis could be explained as a
consequence of inhibition of mRNA synthesis. In addition,
pretreatment of cells with mithramycin enhanced TNF-induced
apoptosis, supporting that inhibition of short-lived repressors may
account for the sensitisation effect of mithramycin.
We have found that in TF-1 cells, TNF activated NF-kBi n
reporter gene assays, without concomitantly inducing cell death.
Similarly, a combination of mithramycin and TNF was shown to
activate NF-kB in a fashion similar to TNF alone. These data argue
for the existence of a mithramycin-sensitive inhibitor that blocked
TNF-induced apoptosis but not TNF-mediated activation of NF-
kB. TNF-mediated NF-kB activation and TNF-induced cell death
bifurcate at TRADD. As in TF-1 cells, TNF-induced apoptosis, but
not TNF-mediated NF-kB activation, required the presence of
mithramycin, and it is postulated that a mithramycin-sensitive
regulator of apoptosis interferes with TNF signalling downstream
of TRADD.
Altogether, FADD is the most likely target of the postulated
mithramycin-sensitive factor, as (i) FADD is a common mediator
of Fas and TNF receptor-induced apoptosis, (ii) in the TNF-
receptor signalling complex, FADD is immediately downstream
TRADD, a molecule that allows TNF-mediated NF-kB activation in
the presence of mithramycin. Cellular FLICE inhibitory proteins
are capable of inhibiting apoptosis induced by several apoptosis-
inducing receptors, through binding to FADD and thus preventing
the recruitment of caspase-8 (Tschopp et al, 1998; Bin et al, 2002).
Previous reports demonstrated that the transcription inhibitor
actinomycin D sensitised cells to TNF-induced apoptosis through
downregulation of cFLIP gene expression (Fulda et al, 2000; Kim
et al, 2000). Similar to actinomycin D, mithramycin-mediated
sensitisation could be explained by the transcription inhibition of
apoptosis inhibitors. Interestingly, mithramycin alone did not
affect the protein level of cFLIP, but strongly downregulated the
expression level of cFLIP in combination with TNF. This would
suggest that, in contrast to the nonspecific transcription inhibitor
actinomycin D, mithramycin may prevent an inducible pathway
that triggers transcription of antiapoptotic genes, such as cFLIP.
Thus, given its selective and low cytotoxic effects, mithramycin
may offer a better alternative to metabolic inhibitors as an
anticancer agent.
The ability of mithramycin to enhance the direct cytotoxic
effects of TNF (and TNF family members) has wide ranging
therapeutic implications. Since the mithramycin/TNF combination
is capable of inducing apoptosis in TF-1 cells independently of the
mitochondrial pathway, combining TNF treatment with mithra-
mycin could have potential for elimination of tumour cells that
express large amounts of Bcl-2. In addition, apoptosis induced by
TNF in the presence of mithramycin was enhanced in three cell
lines with different p53 status. As loss of p53 function contributes
to resistance of some tumour cells to TNF-induced cytotoxicity
(Cai et al, 1997), the present study suggests that combination of
TNF with mithramycin may be a potential strategy to sensitise
mutant p53 TNF-resistant tumour cells.
Recent data indicate that induction of tumour cell death by
stimulation of death receptors such as Fas constitutes a more
prominent mechanism in the defence against tumours than has
been thought previously (French and Tschopp, 2003). As blockade
of death receptor-mediated apoptosis has been implicated in
treatment resistance in vivo, strategies to increase death receptor-
mediated cell death, for example by mithramycin, may prove to be
a useful complementary tool for treatment of cancer. Alternatively,
given the similarity in inducing apoptosis between death receptors,
mithramycin may be expected to enhance tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL)-induced cytotoxicity,
thus representing a novel alternative in cancer therapy. Indeed,
TRAIL or Apo-2L, a member of the TNF family, induces apoptosis
preferentially in tumour cells also through binding to its cognate
death receptors and recruitment of FADD (Walczak and Krammer,
2000). Unlike Fas ligand and TNF, TRAIL appears to have limited
toxicity for mice and monkeys (Walczak et al, 1999), suggesting its
potential value for cancer therapy.
Since mithramycin has been used for many years in the clinic to
treat several types of cancer, the sensitising effect of mithramycin
is not only intriguing but merits further study to realize the full
potential of mithramycin as an adjunctive therapy in death
receptor-mediated apoptosis.
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